Alexion Pharma (ALXN) Beats Q1 EPS Views by 8c
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Join SI Premium – FREE
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) reported Q1 EPS of $0.59, $0.08 better than the analyst estimate of $0.51. Revenue for the quarter came in at $166.1 million versus the consensus estimate of $165.86 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McCormick & Co. (MKC) Tops Q3 EPS by 10c, Beats on Revenue; Offers EPS Guidance
- CollPlant (CLGN) Misses Q2 EPS by 165c
- AAR Corp. (AIR) Tops Q1 EPS by 18c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
